BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
bioAffinity Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.51−0.22 (-5.90%)
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
bioAffinity Technologies, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -209.8%
- Net margin
- -257.3%
- Return on equity, FY2025
- -301.8%
Financial strength
- Current ratio
- 1.44
- Debt to equity
- 0.01
- Debt to assets
- 0.5%
- Cash to current liabilities
- 90.6%
Valuation
- P/E ratio
- –
- Price to sales
- 3.11
- Price to book
- 4.87
- Dividend yield
- –